piperidines and stattic

piperidines has been researched along with stattic* in 2 studies

Reviews

1 review(s) available for piperidines and stattic

ArticleYear
From mechanism to therapies in systemic lupus erythematosus.
    Current opinion in rheumatology, 2017, Volume: 29, Issue:2

    Systemic lupus erythematosus (SLE) is a disabling and deadly disease. Development of novel therapies for SLE has historically been limited by incomplete understanding of immune dysregulation. Recent advances in lupus pathogenesis, however, have led to the adoption or development of new therapeutics, including the first Food and Drug Administration-approved drug in 50 years.. Multiple cytokines (interferon, B lymphocyte stimulator, IL-6, and IL-17), signaling pathways (Bruton's Tyrosine Kinase, Janus kinase/signal transducer and activator of transcription), and immune cells are dysregulated in SLE. In this review, we cover seminal discoveries that demonstrate how this dysregulation is integral to SLE pathogenesis and the novel therapeutics currently under development or in clinical trials. In addition, early work suggests metabolic derangements are another target for disease modification. Finally, molecular profiling has led to improved patient stratification in the heterogeneous SLE population, which may improve clinical trial outcomes and therapeutic selection.. Recent advances in the treatment of SLE have directly resulted from improved understanding of this complicated disease. Rheumatologists may have a variety of novel agents and more precise targeting of select lupus populations in the coming years.

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Activating Factor; Cyclic S-Oxides; Cytokines; Drug Approval; Drug Discovery; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Interleukin-17; Interleukin-6; Isoquinolines; Janus Kinases; Lupus Erythematosus, Systemic; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recombinant Fusion Proteins; Rituximab; Signal Transduction; STAT Transcription Factors

2017

Other Studies

1 other study(ies) available for piperidines and stattic

ArticleYear
Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    International immunopharmacology, 2018, Volume: 58

    Tofacitinib, a small molecule JAK inhibitor, has been widely used to reduce inflammation and inhibit progression of bone destruction in rheumatoid arthritis. STAT3, a downstream signaling molecule of JAK, plays a key role in the activation of signaling in response to inflammatory cytokines. Thus, targeting STAT3 may be an inspiring strategy for treating osteoclast-related diseases such as rheumatoid arthritis. In this study, we first investigated the effects of Stattic, a STAT3 inhibitor, on receptor activator of NF-κB ligand (RANKL)-mediated osteoclastogenesis. Stattic inhibited osteoclast differentiation and bone resorption in RANKL-induced RAW264.7 cells in a dose-dependent manner. Stattic also suppressed RANKL-induced upregulation of osteoclast-related genes tartrate-resistant acid phosphatase, matrix metalloproteinase 9, cathepsin K, RANK, tumor necrosis factor receptor-associated factor 6, and osteoclast-associated receptor in RAW264.7 cells. Moreover, Stattic exhibited an inhibitory effect on cell proliferation and cell cycle progression at higher dosages. At the molecular level, Stattic inhibited RANKL-induced activation of STAT3 and NF-κB pathways, without significantly affecting MAPK signaling. In addition, Stattic inhibited RANKL-induced expression of osteoclast-related transcription factors c-Fos and NFATc1. Importantly, Stattic also prevented bone loss caused by ovariectomy. Together, our data confirm that Stattic restricts osteoclastogenesis and bone loss by disturbing RANKL-induced STAT3 and NF-κB signaling. Thus, Stattic represents a novel type of osteoclast inhibitor that could be useful for conditions such as osteoporosis and rheumatoid arthritis.

    Topics: Animals; Arthritis, Rheumatoid; Bone Resorption; Cyclic S-Oxides; Gene Expression Regulation; Genes, fos; Humans; Janus Kinases; Macrophages; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor

2018